# Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO

> **NCT02800642** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 162 (actual)

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT02800642
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-10
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02800642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02800642, "Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02800642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*